Compare MMT & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | MMT | SWKH |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Diversified Financial Services |
| Sector | Finance | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.2M | 205.9M |
| IPO Year | N/A | 1999 |
| Metric | MMT | SWKH |
|---|---|---|
| Price | $4.68 | $17.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 86.5K | 10.3K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 8.58% | N/A |
| EPS Growth | N/A | ★ 120.89 |
| EPS | 0.30 | ★ 1.85 |
| Revenue | N/A | ★ $40,149,000.00 |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.33 | ★ $9.25 |
| Revenue Growth | N/A | ★ 62.38 |
| 52 Week Low | $4.04 | $13.17 |
| 52 Week High | $4.70 | $20.49 |
| Indicator | MMT | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 49.87 |
| Support Level | $4.63 | $17.00 |
| Resistance Level | $4.69 | $17.30 |
| Average True Range (ATR) | 0.04 | 0.26 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 45.00 | 36.49 |
MFS Multimarket Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests a majority of its net assets in fixed-income securities, corporate bonds of the U.S and foreign issuers, U.S Government securities, foreign government securities, mortgage-backed and other asset-backed securities of U.S and foreign issuers, and debt instruments of issuers located in emerging market countries. The portfolio of investments comprises of different sector investments such as aerospace, airlines, automotive, chemicals, electronics, and others.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.